Global Lucentis (Ranibizumab) and Biosimilar Market Research Report 2023

Lucentis (Ranibizumab) and Biosimilar Market

Ranibizumab is a medication used to manage and treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, myopic choroidal neovascularization, and diabetic retinopathy.

Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Lucentis (Ranibizumab) and Biosimilar market research.

Key manufacturers engaged in the Lucentis (Ranibizumab) and Biosimilar industry include Roche, Coherus and Biogen, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.

When refers to consumption region, % volume of Lucentis (Ranibizumab) and Biosimilar were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Lucentis (Ranibizumab) and Biosimilar market and estimated to attract more attentions from industry insiders and investors.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Lucentis (Ranibizumab) and Biosimilar market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

Scope of Lucentis (Ranibizumab) and Biosimilar Market Report

1.1 Product Overview and Scope of Lucentis (Ranibizumab) and Biosimilar

1.2 Lucentis (Ranibizumab) and Biosimilar Segment by Type

1.2.1 Global Lucentis (Ranibizumab) and Biosimilar Market Value Comparison by Type (2023-2029)

1.2.2 Brand

1.2.3 Biosimilar

1.3 Lucentis (Ranibizumab) and Biosimilar Segment by Application

1.3.1 Global Lucentis (Ranibizumab) and Biosimilar Market Value by Application: (2023-2029)

1.3.2 Hospital

1.3.3 Pharmacy

1.3.4 Other

1.4 Global Lucentis (Ranibizumab) and Biosimilar Market Size Estimates and Forecasts

1.4.1 Global Lucentis (Ranibizumab) and Biosimilar Revenue 2018-2029

1.4.2 Global Lucentis (Ranibizumab) and Biosimilar Sales 2018-2029

1.4.3 Global Lucentis (Ranibizumab) and Biosimilar Market Average Price (2018-2029)

1.5 Assumptions and Limitations

2.1 Global Lucentis (Ranibizumab) and Biosimilar Sales Market Share by Manufacturers (2018-2023)

2.2 Global Lucentis (Ranibizumab) and Biosimilar Revenue Market Share by Manufacturers (2018-2023)

2.3 Global Lucentis (Ranibizumab) and Biosimilar Average Price by Manufacturers (2018-2023)

2.4 Global Lucentis (Ranibizumab) and Biosimilar Industry Ranking 2021 VS 2022 VS 2023

2.5 Global Key Manufacturers of Lucentis (Ranibizumab) and Biosimilar, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Lucentis (Ranibizumab) and Biosimilar, Product Type & Application

2.7 Lucentis (Ranibizumab) and Biosimilar Market Competitive Situation and Trends

2.7.1 Lucentis (Ranibizumab) and Biosimilar Market Concentration Rate

2.7.2 The Global Top 5 and Top 10 Largest Lucentis (Ranibizumab) and Biosimilar Players Market Share by Revenue

2.7.3 Global Lucentis (Ranibizumab) and Biosimilar Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.8 Manufacturers Mergers & Acquisitions, Expansion Plans

3.1 Global Lucentis (Ranibizumab) and Biosimilar Market Size by Region: 2018 Versus 2022 Versus 2029

3.2 Global Lucentis (Ranibizumab) and Biosimilar Global Lucentis (Ranibizumab) and Biosimilar Sales by Region: 2018-2029

3.2.1 Global Lucentis (Ranibizumab) and Biosimilar Sales by Region: 2018-2023

3.2.2 Global Lucentis (Ranibizumab) and Biosimilar Sales by Region: 2024-2029

3.3 Global Lucentis (Ranibizumab) and Biosimilar Global Lucentis (Ranibizumab) and Biosimilar Revenue by Region: 2018-2029

3.3.1 Global Lucentis (Ranibizumab) and Biosimilar Revenue by Region: 2018-2023

3.3.2 Global Lucentis (Ranibizumab) and Biosimilar Revenue by Region: 2024-2029

3.4 North America Lucentis (Ranibizumab) and Biosimilar Market Facts & Figures by Country

3.4.1 North America Lucentis (Ranibizumab) and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029

3.4.2 North America Lucentis (Ranibizumab) and Biosimilar Sales by Country (2018-2029)

3.4.3 North America Lucentis (Ranibizumab) and Biosimilar Revenue by Country (2018-2029)

3.4.4 United States

3.4.5 Canada

3.5 Europe Lucentis (Ranibizumab) and Biosimilar Market Facts & Figures by Country

3.5.1 Europe Lucentis (Ranibizumab) and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029

3.5.2 Europe Lucentis (Ranibizumab) and Biosimilar Sales by Country (2018-2029)

3.5.3 Europe Lucentis (Ranibizumab) and Biosimilar Revenue by Country (2018-2029)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Lucentis (Ranibizumab) and Biosimilar Market Facts & Figures by Country

3.6.1 Asia Pacific Lucentis (Ranibizumab) and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029

3.6.2 Asia Pacific Lucentis (Ranibizumab) and Biosimilar Sales by Country (2018-2029)

3.6.3 Asia Pacific Lucentis (Ranibizumab) and Biosimilar Revenue by Country (2018-2029)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Lucentis (Ranibizumab) and Biosimilar Market Facts & Figures by Country

3.7.1 Latin America Lucentis (Ranibizumab) and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029

3.7.2 Latin America Lucentis (Ranibizumab) and Biosimilar Sales by Country (2018-2029)

3.7.3 Latin America Lucentis (Ranibizumab) and Biosimilar Revenue by Country (2018-2029)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.7.7 Colombia

3.8 Middle East and Africa Lucentis (Ranibizumab) and Biosimilar Market Facts & Figures by Country

3.8.1 Middle East and Africa Lucentis (Ranibizumab) and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029

3.8.2 Middle East and Africa Lucentis (Ranibizumab) and Biosimilar Sales by Country (2018-2029)

3.8.3 Middle East and Africa Lucentis (Ranibizumab) and Biosimilar Revenue by Country (2018-2029)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4.1 Global Lucentis (Ranibizumab) and Biosimilar Sales by Type (2018-2029)

4.1.1 Global Lucentis (Ranibizumab) and Biosimilar Sales by Type (2018-2023)

4.1.2 Global Lucentis (Ranibizumab) and Biosimilar Sales by Type (2024-2029)

4.1.3 Global Lucentis (Ranibizumab) and Biosimilar Sales Market Share by Type (2018-2029)

4.2 Global Lucentis (Ranibizumab) and Biosimilar Revenue by Type (2018-2029)

4.2.1 Global Lucentis (Ranibizumab) and Biosimilar Revenue by Type (2018-2023)

4.2.2 Global Lucentis (Ranibizumab) and Biosimilar Revenue by Type (2024-2029)

4.2.3 Global Lucentis (Ranibizumab) and Biosimilar Revenue Market Share by Type (2018-2029)

4.3 Global Lucentis (Ranibizumab) and Biosimilar Price by Type (2018-2029)

5.1 Global Lucentis (Ranibizumab) and Biosimilar Sales by Application (2018-2029)

5.1.1 Global Lucentis (Ranibizumab) and Biosimilar Sales by Application (2018-2023)

5.1.2 Global Lucentis (Ranibizumab) and Biosimilar Sales by Application (2024-2029)

5.1.3 Global Lucentis (Ranibizumab) and Biosimilar Sales Market Share by Application (2018-2029)

5.2 Global Lucentis (Ranibizumab) and Biosimilar Revenue by Application (2018-2029)

5.2.1 Global Lucentis (Ranibizumab) and Biosimilar Revenue by Application (2018-2023)

5.2.2 Global Lucentis (Ranibizumab) and Biosimilar Revenue by Application (2024-2029)

5.2.3 Global Lucentis (Ranibizumab) and Biosimilar Revenue Market Share by Application (2018-2029)

5.3 Global Lucentis (Ranibizumab) and Biosimilar Price by Application (2018-2029)

6.1 Roche

6.1.1 Roche Corporation Information

6.1.2 Roche Description and Business Overview

6.1.3 Roche Lucentis (Ranibizumab) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)

6.1.4 Roche Lucentis (Ranibizumab) and Biosimilar Product Portfolio

6.1.5 Roche Recent Developments/Updates

6.2 Coherus

6.2.1 Coherus Corporation Information

6.2.2 Coherus Description and Business Overview

6.2.3 Coherus Lucentis (Ranibizumab) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)

6.2.4 Coherus Lucentis (Ranibizumab) and Biosimilar Product Portfolio

6.2.5 Coherus Recent Developments/Updates

6.3 Biogen

6.3.1 Biogen Corporation Information

6.3.2 Biogen Description and Business Overview

6.3.3 Biogen Lucentis (Ranibizumab) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)

6.3.4 Biogen Lucentis (Ranibizumab) and Biosimilar Product Portfolio

6.3.5 Biogen Recent Developments/Updates

7.1 Lucentis (Ranibizumab) and Biosimilar Industry Chain Analysis

7.2 Lucentis (Ranibizumab) and Biosimilar Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Lucentis (Ranibizumab) and Biosimilar Production Mode & Process

7.4 Lucentis (Ranibizumab) and Biosimilar Sales and Marketing

7.4.1 Lucentis (Ranibizumab) and Biosimilar Sales Channels

7.4.2 Lucentis (Ranibizumab) and Biosimilar Distributors

7.5 Lucentis (Ranibizumab) and Biosimilar Customers

8.1 Lucentis (Ranibizumab) and Biosimilar Industry Trends

8.2 Lucentis (Ranibizumab) and Biosimilar Market Drivers

8.3 Lucentis (Ranibizumab) and Biosimilar Market Challenges

8.4 Lucentis (Ranibizumab) and Biosimilar Market Restraints

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

List of Tables

    Table 1. Global Lucentis (Ranibizumab) and Biosimilar Market Value Comparison by Type (2023-2029) & (US$ Million)

    Table 2. Global Lucentis (Ranibizumab) and Biosimilar Market Value Comparison by Application (2023-2029) & (US$ Million)

    Table 3. Global Lucentis (Ranibizumab) and Biosimilar Market Competitive Situation by Manufacturers in 2022

    Table 4. Global Lucentis (Ranibizumab) and Biosimilar Sales (K Units) of Key Manufacturers (2018-2023)

    Table 5. Global Lucentis (Ranibizumab) and Biosimilar Sales Market Share by Manufacturers (2018-2023)

    Table 6. Global Lucentis (Ranibizumab) and Biosimilar Revenue (US$ Million) by Manufacturers (2018-2023)

    Table 7. Global Lucentis (Ranibizumab) and Biosimilar Revenue Share by Manufacturers (2018-2023)

    Table 8. Global Market Lucentis (Ranibizumab) and Biosimilar Average Price (US$/Unit) of Key Manufacturers (2018-2023)

    Table 9. Global Key Players of Lucentis (Ranibizumab) and Biosimilar, Industry Ranking, 2021 VS 2022 VS 2023

    Table 10. Global Key Manufacturers of Lucentis (Ranibizumab) and Biosimilar, Manufacturing Sites & Headquarters

    Table 11. Global Key Manufacturers of Lucentis (Ranibizumab) and Biosimilar, Product Type & Application

    Table 12. Global Key Manufacturers of Lucentis (Ranibizumab) and Biosimilar, Date of Enter into This Industry

    Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

    Table 14. Global Lucentis (Ranibizumab) and Biosimilar by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Lucentis (Ranibizumab) and Biosimilar as of 2022)

    Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

    Table 16. Global Lucentis (Ranibizumab) and Biosimilar Market Size by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 17. Global Lucentis (Ranibizumab) and Biosimilar Sales by Region (2018-2023) & (K Units)

    Table 18. Global Lucentis (Ranibizumab) and Biosimilar Sales Market Share by Region (2018-2023)

    Table 19. Global Lucentis (Ranibizumab) and Biosimilar Sales by Region (2024-2029) & (K Units)

    Table 20. Global Lucentis (Ranibizumab) and Biosimilar Sales Market Share by Region (2024-2029)

    Table 21. Global Lucentis (Ranibizumab) and Biosimilar Revenue by Region (2018-2023) & (US$ Million)

    Table 22. Global Lucentis (Ranibizumab) and Biosimilar Revenue Market Share by Region (2018-2023)

    Table 23. Global Lucentis (Ranibizumab) and Biosimilar Revenue by Region (2024-2029) & (US$ Million)

    Table 24. Global Lucentis (Ranibizumab) and Biosimilar Revenue Market Share by Region (2024-2029)

    Table 25. North America Lucentis (Ranibizumab) and Biosimilar Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)

    Table 26. North America Lucentis (Ranibizumab) and Biosimilar Sales by Country (2018-2023) & (K Units)

    Table 27. North America Lucentis (Ranibizumab) and Biosimilar Sales by Country (2024-2029) & (K Units)

    Table 28. North America Lucentis (Ranibizumab) and Biosimilar Revenue by Country (2018-2023) & (US$ Million)

    Table 29. North America Lucentis (Ranibizumab) and Biosimilar Revenue by Country (2024-2029) & (US$ Million)

    Table 30. Europe Lucentis (Ranibizumab) and Biosimilar Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)

    Table 31. Europe Lucentis (Ranibizumab) and Biosimilar Sales by Country (2018-2023) & (K Units)

    Table 32. Europe Lucentis (Ranibizumab) and Biosimilar Sales by Country (2024-2029) & (K Units)

    Table 33. Europe Lucentis (Ranibizumab) and Biosimilar Revenue by Country (2018-2023) & (US$ Million)

    Table 34. Europe Lucentis (Ranibizumab) and Biosimilar Revenue by Country (2024-2029) & (US$ Million)

    Table 35. Asia Pacific Lucentis (Ranibizumab) and Biosimilar Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)

    Table 36. Asia Pacific Lucentis (Ranibizumab) and Biosimilar Sales by Region (2018-2023) & (K Units)

    Table 37. Asia Pacific Lucentis (Ranibizumab) and Biosimilar Sales by Region (2024-2029) & (K Units)

    Table 38. Asia Pacific Lucentis (Ranibizumab) and Biosimilar Revenue by Region (2018-2023) & (US$ Million)

    Table 39. Asia Pacific Lucentis (Ranibizumab) and Biosimilar Revenue by Region (2024-2029) & (US$ Million)

    Table 40. Latin America Lucentis (Ranibizumab) and Biosimilar Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)

    Table 41. Latin America Lucentis (Ranibizumab) and Biosimilar Sales by Country (2018-2023) & (K Units)

    Table 42. Latin America Lucentis (Ranibizumab) and Biosimilar Sales by Country (2024-2029) & (K Units)

    Table 43. Latin America Lucentis (Ranibizumab) and Biosimilar Revenue by Country (2018-2023) & (US$ Million)

    Table 44. Latin America Lucentis (Ranibizumab) and Biosimilar Revenue by Country (2024-2029) & (US$ Million)

    Table 45. Middle East & Africa Lucentis (Ranibizumab) and Biosimilar Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)

    Table 46. Middle East & Africa Lucentis (Ranibizumab) and Biosimilar Sales by Country (2018-2023) & (K Units)

    Table 47. Middle East & Africa Lucentis (Ranibizumab) and Biosimilar Sales by Country (2024-2029) & (K Units)

    Table 48. Middle East & Africa Lucentis (Ranibizumab) and Biosimilar Revenue by Country (2018-2023) & (US$ Million)

    Table 49. Middle East & Africa Lucentis (Ranibizumab) and Biosimilar Revenue by Country (2024-2029) & (US$ Million)

    Table 50. Global Lucentis (Ranibizumab) and Biosimilar Sales (K Units) by Type (2018-2023)

    Table 51. Global Lucentis (Ranibizumab) and Biosimilar Sales (K Units) by Type (2024-2029)

    Table 52. Global Lucentis (Ranibizumab) and Biosimilar Sales Market Share by Type (2018-2023)

    Table 53. Global Lucentis (Ranibizumab) and Biosimilar Sales Market Share by Type (2024-2029)

    Table 54. Global Lucentis (Ranibizumab) and Biosimilar Revenue (US$ Million) by Type (2018-2023)

    Table 55. Global Lucentis (Ranibizumab) and Biosimilar Revenue (US$ Million) by Type (2024-2029)

    Table 56. Global Lucentis (Ranibizumab) and Biosimilar Revenue Market Share by Type (2018-2023)

    Table 57. Global Lucentis (Ranibizumab) and Biosimilar Revenue Market Share by Type (2024-2029)

    Table 58. Global Lucentis (Ranibizumab) and Biosimilar Price (US$/Unit) by Type (2018-2023)

    Table 59. Global Lucentis (Ranibizumab) and Biosimilar Price (US$/Unit) by Type (2024-2029)

    Table 60. Global Lucentis (Ranibizumab) and Biosimilar Sales (K Units) by Application (2018-2023)

    Table 61. Global Lucentis (Ranibizumab) and Biosimilar Sales (K Units) by Application (2024-2029)

    Table 62. Global Lucentis (Ranibizumab) and Biosimilar Sales Market Share by Application (2018-2023)

    Table 63. Global Lucentis (Ranibizumab) and Biosimilar Sales Market Share by Application (2024-2029)

    Table 64. Global Lucentis (Ranibizumab) and Biosimilar Revenue (US$ Million) by Application (2018-2023)

    Table 65. Global Lucentis (Ranibizumab) and Biosimilar Revenue (US$ Million) by Application (2024-2029)

    Table 66. Global Lucentis (Ranibizumab) and Biosimilar Revenue Market Share by Application (2018-2023)

    Table 67. Global Lucentis (Ranibizumab) and Biosimilar Revenue Market Share by Application (2024-2029)

    Table 68. Global Lucentis (Ranibizumab) and Biosimilar Price (US$/Unit) by Application (2018-2023)

    Table 69. Global Lucentis (Ranibizumab) and Biosimilar Price (US$/Unit) by Application (2024-2029)

    Table 70. Roche Corporation Information

    Table 71. Roche Description and Business Overview

    Table 72. Roche Lucentis (Ranibizumab) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

    Table 73. Roche Lucentis (Ranibizumab) and Biosimilar Product

    Table 74. Roche Recent Developments/Updates

    Table 75. Coherus Corporation Information

    Table 76. Coherus Description and Business Overview

    Table 77. Coherus Lucentis (Ranibizumab) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

    Table 78. Coherus Lucentis (Ranibizumab) and Biosimilar Product

    Table 79. Coherus Recent Developments/Updates

    Table 80. Biogen Corporation Information

    Table 81. Biogen Description and Business Overview

    Table 82. Biogen Lucentis (Ranibizumab) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

    Table 83. Biogen Lucentis (Ranibizumab) and Biosimilar Product

    Table 84. Biogen Recent Developments/Updates

    Table 85. Key Raw Materials Lists

    Table 86. Raw Materials Key Suppliers Lists

    Table 87. Lucentis (Ranibizumab) and Biosimilar Distributors List

    Table 88. Lucentis (Ranibizumab) and Biosimilar Customers List

    Table 89. Lucentis (Ranibizumab) and Biosimilar Market Trends

    Table 90. Lucentis (Ranibizumab) and Biosimilar Market Drivers

    Table 91. Lucentis (Ranibizumab) and Biosimilar Market Challenges

    Table 92. Lucentis (Ranibizumab) and Biosimilar Market Restraints

    Table 93. Research Programs/Design for This Report

    Table 94. Key Data Information from Secondary Sources

    Table 95. Key Data Information from Primary Sources

List of Figures

    Figure 1. Product Picture of Lucentis (Ranibizumab) and Biosimilar

    Figure 2. Global Lucentis (Ranibizumab) and Biosimilar Market Value Comparison by Type (2023-2029) & (US$ Million)

    Figure 3. Global Lucentis (Ranibizumab) and Biosimilar Market Share by Type in 2022 & 2029

    Figure 4. Brand Product Picture

    Figure 5. Biosimilar Product Picture

    Figure 6. Global Lucentis (Ranibizumab) and Biosimilar Market Value Comparison by Application (2023-2029) & (US$ Million)

    Figure 7. Global Lucentis (Ranibizumab) and Biosimilar Market Share by Application in 2022 & 2029

    Figure 8. Hospital

    Figure 9. Pharmacy

    Figure 10. Other

    Figure 11. Global Lucentis (Ranibizumab) and Biosimilar Revenue, (US$ Million), 2018 VS 2022 VS 2029

    Figure 12. Global Lucentis (Ranibizumab) and Biosimilar Market Size (2018-2029) & (US$ Million)

    Figure 13. Global Lucentis (Ranibizumab) and Biosimilar Sales (2018-2029) & (K Units)

    Figure 14. Global Lucentis (Ranibizumab) and Biosimilar Average Price (US$/Unit) & (2018-2029)

    Figure 15. Lucentis (Ranibizumab) and Biosimilar Report Years Considered

    Figure 16. Lucentis (Ranibizumab) and Biosimilar Sales Share by Manufacturers in 2022

    Figure 17. Global Lucentis (Ranibizumab) and Biosimilar Revenue Share by Manufacturers in 2022

    Figure 18. The Global 5 and 10 Largest Lucentis (Ranibizumab) and Biosimilar Players: Market Share by Revenue in 2022

    Figure 19. Lucentis (Ranibizumab) and Biosimilar Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022

    Figure 20. Global Lucentis (Ranibizumab) and Biosimilar Market Size by Region (US$ Million): 2018 VS 2022 VS 2029

    Figure 21. North America Lucentis (Ranibizumab) and Biosimilar Sales Market Share by Country (2018-2029)

    Figure 22. North America Lucentis (Ranibizumab) and Biosimilar Revenue Market Share by Country (2018-2029)

    Figure 23. United States Lucentis (Ranibizumab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 24. Canada Lucentis (Ranibizumab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 25. Europe Lucentis (Ranibizumab) and Biosimilar Sales Market Share by Country (2018-2029)

    Figure 26. Europe Lucentis (Ranibizumab) and Biosimilar Revenue Market Share by Country (2018-2029)

    Figure 27. Germany Lucentis (Ranibizumab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 28. France Lucentis (Ranibizumab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 29. U.K. Lucentis (Ranibizumab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 30. Italy Lucentis (Ranibizumab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 31. Russia Lucentis (Ranibizumab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 32. Asia Pacific Lucentis (Ranibizumab) and Biosimilar Sales Market Share by Region (2018-2029)

    Figure 33. Asia Pacific Lucentis (Ranibizumab) and Biosimilar Revenue Market Share by Region (2018-2029)

    Figure 34. China Lucentis (Ranibizumab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 35. Japan Lucentis (Ranibizumab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 36. South Korea Lucentis (Ranibizumab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 37. India Lucentis (Ranibizumab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 38. Australia Lucentis (Ranibizumab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 39. China Taiwan Lucentis (Ranibizumab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 40. Southeast Asia Lucentis (Ranibizumab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 41. Latin America Lucentis (Ranibizumab) and Biosimilar Sales Market Share by Country (2018-2029)

    Figure 42. Latin America Lucentis (Ranibizumab) and Biosimilar Revenue Market Share by Country (2018-2029)

    Figure 43. Mexico Lucentis (Ranibizumab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 44. Brazil Lucentis (Ranibizumab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 45. Argentina Lucentis (Ranibizumab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 46. Colombia Lucentis (Ranibizumab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 47. Middle East & Africa Lucentis (Ranibizumab) and Biosimilar Sales Market Share by Country (2018-2029)

    Figure 48. Middle East & Africa Lucentis (Ranibizumab) and Biosimilar Revenue Market Share by Country (2018-2029)

    Figure 49. Turkey Lucentis (Ranibizumab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 50. Saudi Arabia Lucentis (Ranibizumab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 51. UAE Lucentis (Ranibizumab) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 52. Global Sales Market Share of Lucentis (Ranibizumab) and Biosimilar by Type (2018-2029)

    Figure 53. Global Revenue Market Share of Lucentis (Ranibizumab) and Biosimilar by Type (2018-2029)

    Figure 54. Global Lucentis (Ranibizumab) and Biosimilar Price (US$/Unit) by Type (2018-2029)

    Figure 55. Global Sales Market Share of Lucentis (Ranibizumab) and Biosimilar by Application (2018-2029)

    Figure 56. Global Revenue Market Share of Lucentis (Ranibizumab) and Biosimilar by Application (2018-2029)

    Figure 57. Global Lucentis (Ranibizumab) and Biosimilar Price (US$/Unit) by Application (2018-2029)

    Figure 58. Lucentis (Ranibizumab) and Biosimilar Value Chain

    Figure 59. Lucentis (Ranibizumab) and Biosimilar Production Process

    Figure 60. Channels of Distribution (Direct Vs Distribution)

    Figure 61. Distributors Profiles

    Figure 62. Bottom-up and Top-down Approaches for This Report

    Figure 63. Data Triangulation

    Figure 64. Key Executives Interviewed